DRUGS PROFILING, QUANTIFICATION OF RIF/RESISTANCE OF MYCOBACTERIUM TUBERCULOSIS BY USING AUTOMATED GENEXPERT: A DIAGNOSTIC CHALLENGE

Main Article Content

Awais khan
Tasneem Noor Mohammad
Aamna Shah
Sumbal Nosheen
Muhammad Zahid Ali

Keywords

GeneXpert MTB/RIF system, Drugs profiling, Mycobacterium tuberculosis, RIF/ resistance detected, World Health

Abstract

The study was conducted from February 2022 to January 2023 with permission of the National Tuberculosis Control Program and Tertiary care Hospitals, Peshawar. Among a total of 1,390 individuals, 621 (44.6%) were male and 769 (55.5%) were female. Regarding Mycobacterium tuberculosis types, there were 1,153 cases (83%) of pulmonary TB, 237 cases (17%) of extra-pulmonary TB, 571 cases of Mycobacterium tuberculosis detection with low levels, and no detection of RIF/resistance genes. Additionally, there were 623 cases of Mycobacterium tuberculosis detection with medium levels, with 2 cases of RIF/resistance detected, and 196 cases of Mycobacterium tuberculosis detection with high levels, with 38 cases of RIF/resistance detected. First-line treatment was recommended for 457 patients (32.8%), with a mean of 244 (±106). Second-line treatment was recommended for 40 patients (2.8%), with a mean of 21.4 (±9.2). New patients accounted for 893 cases (64.2%), with a mean of 478.6 (±207). In recent times, there have been significant advancements in desktop technology, particularly the GeneXpert MTB/RIF system. This system has proven to be effective in detecting Mycobacterium tuberculosis in specific population groups, enabling prompt identification of drug resistance in infected patients.

Abstract 151 | pdf Downloads 62

References

1. AFTAB, A., AFZAL, S., QAMAR, Z. & IDREES, M. J. S. R. 2021. Early detection of MDR Mycobacterium tuberculosis mutations in Pakistan. 11, 1-5.
2. AGRAWAL, M., BAJAJ, A., BHATIA, V., DUTT, S. J. J. O. C. & JCDR, D. R. 2016. Comparative study of GeneXpert with ZN stain and culture in samples of suspected pulmonary tuberculosis. 10, DC09.
3. AHMAD, T., KHAN, M., KHAN, M. M., EJETA, E., KARAMI, M. & OHIA, C. J. I. J. O. M. 2017. Treatment outcome of tuberculosis patients under directly observed treatment short course and its determinants in Shangla, Khyber-Pakhtunkhwa, Pakistan: a retrospective study. 6, 360.
4. AKHTAR, A. M., ARIF, M. A., KANWAL, S. & MAJEED, S. J. J. P. M. A. 2016. Prevalence and drug resistance pattern of MDR TB in retreatment cases of Punjab, Pakistan. 66, 989-3.
5. ALI, S., KHAN, M. T., KHAN, A. S., MOHAMMAD, N., KHAN, M. M., AHMAD, S., NOOR, S., JABBAR, A., DAIRE, C. & HASSAN, F. J. P. J. O. M. 2020. Prevalence of multi-drug resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa–a high tuberculosis endemic area of Pakistan. 69, 133-137.
6. CHA, J., THWAITES, G. E. & ASHTON, P. M. J. M. 2020. An evaluation of progress towards the 2035 WHO End TB targets in 40 high burden countries.
7. HAMEED, H. A., ISLAM, M. M., CHHOTARAY, C., WANG, C., LIU, Y., TAN, Y., LI, X., TAN, S., DELORME, V., YEW, W. W. J. F. I. C. & MICROBIOLOGY, I. 2018. Molecular targets related drug resistance mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis strains. 8, 114.
8. HASAN, Z., TANVEER, M., KANJI, A., HASAN, Q., GHEBREMICHAEL, S. & HASAN, R. J. J. O. C. M. 2006. Spoligotyping of Mycobacterium tuberculosis isolates from Pakistan reveals predominance of Central Asian Strain 1 and Beijing isolates. 44, 1763-1768.
9. HOAGLAND, D. T., LIU, J., LEE, R. B. & LEE, R. E. J. A. D. D. R. 2016. New agents for the treatment of drug-resistant Mycobacterium tuberculosis. 102, 55-72.
10. KOCH, A. & MIZRAHI, V. J. T. I. M. 2018. Mycobacterium tuberculosis. 26, 555-556.
11. RIOJAS, M. A., MCGOUGH, K. J., RIDER-RIOJAS, C. J., RASTOGI, N., HAZBÓN, M. H. J. I. J. O. S. & MICROBIOLOGY, E. 2018. Phylogenomic analysis of the species of the Mycobacterium tuberculosis complex demonstrates that Mycobacterium africanum, Mycobacterium bovis, Mycobacterium caprae, Mycobacterium microti and Mycobacterium pinnipedii are later heterotypic synonyms of Mycobacterium tuberculosis. 68, 324-332.
12. TAGLIANI, E., ALAGNA, R., TAFAJ, S., HAFIZI, H. & CIRILLO, D. M. J. B. I. D. 2017. Evaluation of Mycobacterium tuberculosis viability in OMNIgene-SPUTUM reagent upon multi-day transport at ambient temperature. 17, 1-5.
13. TAHSEEN, S., KHANZADA, F. M., BALOCH, A. Q., ABBAS, Q., BHUTTO, M. M., ALIZAI, A. W., ZAMAN, S., QASIM, Z., DURRANI, M. N. & FAROUGH, M. K. J. P. O. 2020. Extrapulmonary tuberculosis in Pakistan-A nation-wide multicenter retrospective study. 15, e0232134.
14. ULLAH, I., JAVAID, A., TAHIR, Z., ULLAH, O., SHAH, A. A., HASAN, F. & AYUB, N. J. P. O. 2016. Pattern of drug resistance and risk factors associated with development of drug resistant Mycobacterium tuberculosis in Pakistan. 11, e0147529.
15. ULLAH, S., KHAN, M. A., FAROOQ, M., GUL, T. J. M. & SIMULATION, C. I. 2019. Modeling and analysis of tuberculosis (TB) in Khyber Pakhtunkhwa, Pakistan. 165, 181-199.
16. UPLEKAR, M., WEIL, D., LONNROTH, K., JARAMILLO, E., LIENHARDT, C., DIAS, H. M., FALZON, D., FLOYD, K., GARGIONI, G. & GETAHUN, H. J. T. L. 2015. WHO's new end TB strategy. 385, 1799-1801.
17. WALTER, N. D., DOLGANOV, G. M., GARCIA, B. J., WORODRIA, W., ANDAMA, A., MUSISI, E., AYAKAKA, I., VAN, T. T., VOSKUIL, M. I. & DE JONG, B. C. J. T. J. O. I. D. 2015. Transcriptional adaptation of drug-tolerant Mycobacterium tuberculosis during treatment of human tuberculosis. 212, 990-998.
18. YATES, T. A., KHAN, P. Y., KNIGHT, G. M., TAYLOR, J. G., MCHUGH, T. D., LIPMAN, M., WHITE, R. G., COHEN, T., COBELENS, F. G. & WOOD, R. J. T. L. I. D. 2016. The transmission of Mycobacterium tuberculosis in high burden settings. 16, 227-238.

Most read articles by the same author(s)